Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I5QX
|
||||
Former ID |
DIB003697
|
||||
Drug Name |
Etanercept
|
||||
Synonyms |
Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon
|
||||
Drug Type |
Monoclonal antibody
|
||||
Indication | Active rheumatoid arthritis [ICD9: 714; ICD10:M05, M06] | Approved | [556264] | ||
Sciatica [ICD10:M54.3-M54.4] | Phase 3 | [526617], [541869] | |||
Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis [ICD10:C91-C95, J45, J84.1, L80, M081, M45, M35.0, M40-M54, T86.0] | Phase 2 | [889316], [889317], [889318], [889319], [889323], [889324], [889328], [889329], [889330], [889331], [889332], [889333], [889334], [889346], [889362], [889363], [889384], [889419] | |||
Company |
AstraZeneca
|
||||
Target and Pathway | |||||
Target(s) | TNF receptor | Target Info | Modulator | [526617] | |
Tumor necrosis factor | Target Info | Modulator | [889443] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Cytokine-cytokine receptor interaction | |||||
NF-kappa B signaling pathway | |||||
Sphingolipid signaling pathway | |||||
mTOR signaling pathway | |||||
Apoptosis | |||||
TGF-beta signaling pathway | |||||
Osteoclast differentiation | |||||
Antigen processing and presentation | |||||
Toll-like receptor signaling pathway | |||||
NOD-like receptor signaling pathway | |||||
RIG-I-like receptor signaling pathway | |||||
Hematopoietic cell lineage | |||||
Natural killer cell mediated cytotoxicity | |||||
T cell receptor signaling pathway | |||||
Fc epsilon RI signaling pathway | |||||
TNF signaling pathway | |||||
Adipocytokine signaling pathway | |||||
Type II diabetes mellitus | |||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Type I diabetes mellitus | |||||
Alzheimer's disease | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Pertussis | |||||
Legionellosis | |||||
Leishmaniasis | |||||
Chagas disease (American trypanosomiasis) | |||||
African trypanosomiasis | |||||
Malaria | |||||
Toxoplasmosis | |||||
Amoebiasis | |||||
Tuberculosis | |||||
Hepatitis C | |||||
Hepatitis B | |||||
Influenza A | |||||
HTLV-I infection | |||||
Herpes simplex infection | |||||
Proteoglycans in cancer | |||||
Asthma | |||||
Inflammatory bowel disease (IBD) | |||||
Systemic lupus erythematosus | |||||
Rheumatoid arthritis | |||||
Allograft rejection | |||||
Graft-versus-host disease | |||||
Hypertrophic cardiomyopathy (HCM) | |||||
Dilated cardiomyopathy | |||||
PANTHER Pathway | Apoptosis signaling pathway | ||||
Wnt signaling pathway | |||||
Pathway Interaction Database | IL27-mediated signaling events | ||||
Canonical NF-kappaB pathway | |||||
Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
Signaling events mediated by HDAC Class I | |||||
TNF receptor signaling pathway | |||||
Ceramide signaling pathway | |||||
amb2 Integrin signaling | |||||
RXR and RAR heterodimerization with other nuclear receptor | |||||
IL23-mediated signaling events | |||||
HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||||
Caspase Cascade in Apoptosis | |||||
Cellular roles of Anthrax toxin | |||||
Downstream signaling in naï | |||||
PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
WikiPathways | Toll-like receptor signaling pathway | ||||
Monoamine Transport | |||||
SIDS Susceptibility Pathways | |||||
TGF Beta Signaling Pathway | |||||
Cytokines and Inflammatory Response | |||||
MAPK Signaling Pathway | |||||
EV release from cardiac cells and their functional effects | |||||
FAS pathway and Stress induction of HSP regulation | |||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
Cardiac Hypertrophic Response | |||||
Transcriptional Regulation of White Adipocyte Differentiation | |||||
Aryl Hydrocarbon Receptor | |||||
Apoptosis | |||||
Nanoparticle triggered regulated necrosis | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Adipogenesis | |||||
Allograft Rejection | |||||
TNF alpha Signaling Pathway | |||||
TWEAK Signaling Pathway | |||||
Extrinsic Pathway for Apoptosis | |||||
Folate Metabolism | |||||
MicroRNAs in cardiomyocyte hypertrophy | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
Regulation of toll-like receptor signaling pathway | |||||
Matrix Metalloproteinases | |||||
References | |||||
Ref 526617 | Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. | ||||
Ref 541869 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6789). | ||||
Ref 556264 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
Ref 889316 | ClinicalTrials.gov (NCT00001901) Etanercept to Treat Wegener's Granulomatosis | ||||
Ref 889317 | ClinicalTrials.gov (NCT00001954) Etanercept Therapy for Sjogren's Syndrome | ||||
Ref 889318 | ClinicalTrials.gov (NCT00005007) Etanercept for Wegener's Granulomatosis | ||||
Ref 889319 | ClinicalTrials.gov (NCT00006070) Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction | ||||
Ref 889323 | ClinicalTrials.gov (NCT00034060) The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept | ||||
Ref 889324 | ClinicalTrials.gov (NCT00063869) Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | ||||
Ref 889328 | ClinicalTrials.gov (NCT00107991) Etanercept for Treatment of Hidradenitis | ||||
Ref 889329 | ClinicalTrials.gov (NCT00134368) Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo | ||||
Ref 889330 | ClinicalTrials.gov (NCT00135720) Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | ||||
Ref 889331 | ClinicalTrials.gov (NCT00141713) The Use of Etanercept (Enbrel) in the Treatment of Acute Graft-Versus-Host Disease | ||||
Ref 889332 | ClinicalTrials.gov (NCT00141726) Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | ||||
Ref 889333 | ClinicalTrials.gov (NCT00141739) Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) | ||||
Ref 889334 | ClinicalTrials.gov (NCT00141791) Study Evaluating Etanercept in Moderate to Severe Asthma | ||||
Ref 889346 | ClinicalTrials.gov (NCT00509600) Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | ||||
Ref 889362 | ClinicalTrials.gov (NCT01289730) Etanercept (Enbrel) in Undifferentiated Spondyloarthritis | ||||
Ref 889363 | ClinicalTrials.gov (NCT01289743) Etanercept (Enbrel) in Ankylosing Spondylitis | ||||
Ref 889384 | ClinicalTrials.gov (NCT01730495) Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome | ||||
Ref 889419 | ClinicalTrials.gov (NCT02656082) Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.